Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Opinion
Video

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
© 2025 MJH Life Sciences

All rights reserved.